Compare Cassava Sciences Inc (FLNA) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs VanEck Vietnam ETF — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while VanEck Vietnam ETF trades at $16.71 (market cap $469.76M). The key difference: VanEck Vietnam ETF is far larger — about 11.9× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 375,157). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and VanEck Vietnam ETF for 51 Days on average.
| FLNA | VNM | |
|---|---|---|
Market Cap | $39.40M | $469.76M |
Volume | 759,018 | 375,157 |
Sector | Health | Sector/Thematic |
52-Week High | $4.64 | $19.80 |
52-Week Low | $0.68 | $16.34 |
Typical Hold Time | 37 Days | 51 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
VNM trades at $16.87, down 0.35% today, with a bearish technical signal from moving averages. The ETF faces sector concentration risks in real estate and financials while offering exposure to Vietnam's long-term growth potential. Recent news indicates Vietnam is nearing a trade deal with the US, which could provide macroeconomic support.
The outlook remains cautious due to technical weakness and sector headwinds, though selective capital rotation away from AI-heavy markets may benefit Vietnam-focused assets. Key risks include interest rate volatility and concentrated sector exposure limiting near-term upside despite fair valuations around 15x P/E.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
